Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720304 · ClinicalTrials.gov registry record · Phase 2
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT00720304 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 43 participants.
The verdict
NCT00720304, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving erlotinib together with docetaxel and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well erlotinib given together with docetaxel and radiation therapy works in treating patients with stage III or stage IV squamous cell carcinoma of the head and neck.
Interventions
- DRUG docetaxel
- GENETIC polymerase chain reaction
- OTHER immunoenzyme technique
- DRUG erlotinib hydrochloride
- GENETIC fluorescence in situ hybridization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2007-11-19 |
| Est. Completion | 2015-11-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00720304
The ClinicalTrials.gov registry entry for NCT00720304 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which docetaxel is the first listed.
NCT00720304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00720304 about?
NCT00720304 is a clinical study titled "Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck". RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy us...
What is the current status of trial NCT00720304?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2007-11-19. Estimated completion is 2015-11-13.
What interventions are being tested in trial NCT00720304?
The interventions under investigation include: docetaxel (DRUG), polymerase chain reaction (GENETIC), immunoenzyme technique (OTHER), erlotinib hydrochloride (DRUG), fluorescence in situ hybridization (GENETIC).
Who is sponsoring clinical trial NCT00720304?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.